BRCA1 and breast carcinoma: The translational alignment of our preclinical findings with existing and emerging clinical paradigms positions the Brca1co/coMMTV-Cre mouse as an optimal platform for accelerated evaluation of next‐generation combination therapies targeting BRCA1‐deficient breast cancer.